Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Summit Therapeutics to present pre-clinical data that reveals potential of DMD treatment

Summit remains on track to report initial results of its Phase II trial of ezutromid treatment for duchenne muscular dystrophy in the first quarter of 2018
Summit
Summit is set to report the first results of ezutromid treatment in boys with DMD

Drug discovery company Summit Therapeutics PLC (LON:SUMM) is set to present pre-clinical data from the University of Oxford highlighting the potential of its utrophin modulation programme in treating duchenne muscular dystrophy (DMD), a muscle wasting disease.

The company's scientific adviser and co-founder, Professor Kay Davies from the University of Oxford, will present the findings during presentations at the 15th Action Duchenne International Conference 2017 on November 10-12, 2017, in Birmingham, UK.

WATCH: Summit Therapeutics in a great position nearing the business end of its development

The data shows that continuously expressing utrophin in a dystrophin-deficient background can reduce mitochondrial aberration and oxidative stress, Summit said in a statement on Thursday.

Summit's own presentations will focus on the ongoing Phase II proof of concept clinical trial, PhaseOut DMD, which is evaluating its lead utrophin modulator, ezutromid.

PhaseOut DMD, a 48-week open-label clinical trial, has enrolled 40 patients with DMD.

The data for the first 24 weeks of the trial is expected to be reported in the first quarter of 2018 and Summit said this assessment could provide initial clinical proof of mechanism for ezutromid.

READ: Summit Therapeutics enters revenue sharing agreement with Wellcome Trust for ridinilazole

"We remain on-track to report the first results of ezutromid treatment in boys with DMD in PhaseOut DMD in the first quarter of 2018, and if results provide evidence of the mechanism of utrophin modulation in patients, we believe it would represent a major advancement for ezutromid,” said Dr David Roblin, chief operating officer and medical officer at Summit.

“It would bring closer to all patients a therapy that has the potential to be disease modifying in DMD."

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Newswire
October 04 2017

Related Articles

blood_56ceb82789b61.jpg
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
picture of drug research
August 22 2017
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders
e-Therapeutics
August 17 2017
E-Therapeutics’ network-driven drug discovery platform looks at the broader interactions within disease mechanisms

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use